Showing 1 - 4 results of 4 for search 'Lars van der Veen', query time: 0.03s Refine Results
  1. 1
    P1114: HIGHLY SELECTIVE ALLOSTERIC MODULATOR OF THE PHOSPHOINOSITIDE 3-KINASE DELTA (PI3KΔ) ROGINOLISIB (IOA-244) IN A DOSE ESCALATION STUDY OF PATIENTS WITH REFRACTORY/RELAPSED FOLLICULAR LYMPHOMA (FL)

    P1114: HIGHLY SELECTIVE ALLOSTERIC MODULATOR OF THE PHOSPHOINOSITIDE 3-KINASE DELTA (PI3KΔ) ROGINOLISIB (IOA-244) IN A DOSE ESCALATION STUDY OF PATIENTS WITH REFRACTORY/RELAPSED FO... by Carmelo Carlo-Stella, Michael Lahn, Tracey Hammett, Lars van der Veen, Rebeca Zorrilla, Catherine Pickering, Armando Santoro

    Published 2023-08-01
    Get full text
    Article
  2. 2
    469 Combining a safe PI3Kd inhibitor with chemotherapy and anti-PD1 in immunotherapy-refractory NSCLC: a proof-of-concept study to allow clinical trial design

    469 Combining a safe PI3Kd inhibitor with chemotherapy and anti-PD1 in immunotherapy-refractory NSCLC: a proof-of-concept study to allow clinical trial design by Silvia Novello, Chiara Riganti, Luisella Righi, Fabrizio Tabbò, Lars van der Veen, Michael Lahn, Giusy Di Conza, Giorgio Scagliotti, Laurence Neff

    Published 2023-11-01
    Article
  3. 3
    The highly selective and oral phosphoinositide 3-kinase delta (PI3K-δ) inhibitor roginolisib induces apoptosis in mesothelioma cells and increases immune effector cell composition

    The highly selective and oral phosphoinositide 3-kinase delta (PI3K-δ) inhibitor roginolisib induces apoptosis in mesothelioma cells and increases immune effector cell composition by Claudia Kalla, German Ott, Francesca Finotello, Karolina Niewola-Staszkowska, Giusy Di Conza, Michael Lahn, Lars van der Veen, Julia Schüler, Roger Falkenstern-Ge, Joanna Kopecka, Chiara Riganti

    Published 2024-05-01
    Get full text
    Article
  4. 4
    922 A novel autotaxin inhibitor, IOA-289, modulates tumor, immune and stromal cell function and has monotherapy activity in fibrotic cancer models

    922 A novel autotaxin inhibitor, IOA-289, modulates tumor, immune and stromal cell function and has monotherapy activity in fibrotic cancer models by Zoe Johnson, Alan Carruthers, Elisa Matas-Rico, Marcel Deken, Karolina Niewola, Ragini Medhi, Anne Cheasty, Olivier Peyruchaud, Amy Fraser, Pritom Shah, Wouter Moolenaar, Lars van der Veen, Michael Lahn

    Published 2021-11-01
    Article

Search Tools: